Skip to content
DataLookout
Menu

MAINTAIN-POPNCT06925061

Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 20 words
    • Primary completion pushed from Sep 13, 2026 to Dec 31, 2026
    • Interventions: After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment… to After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment…
  2. Minor Study description expanded, about 214 words
    • Site details revised at 9 of 12 sites
    v3
  3. Minor Start date: Mar 13, 2025 to Mar 31, 2025v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To compare the distribution of endoscopic modified Rutgeerts scores, as centrally assessed, at 6 months post-surgery in patients with CD treated with EXL01 to patients treated with placebo.
Timeframe: From enrollment to the end of treatment at 24 weeks

Arms and interventions

Live biotherapeutic product (EXL01)Experimental

EXL01 administered with or without SoC treatment orally, once a day during 24 weeks

PlaceboPlacebo comparator

Placebo administered with or without SoC treatment orally, once a day during 24 weeks

Drugs: After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks

Sites

12 sites in 1 country